NCT01571661View on ClinicalTrials.gov

A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

January 31, 2005

Study Completion Date

January 31, 2005

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

GSK189075A

20mg, 50mg, 150mg, 500mg, 1000mg or Placebo

OTHER

Placebo

Placebo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01571661 - A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter